Immune Design Corp.

We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. Although we believe our approaches have broad potential across multiple therapeutic areas, we are focused in oncology and have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Our two primary product candidates, CMB305 and G100, utilize distinct immuno-oncology approaches that, we believe, address the shortcomings of existing therapies and have the potential to treat a broad patient population either as individual therapies or in combination with other mechanisms of action.Our immuno-oncology product candidates are being developed in two separate approaches: one that targets specific antigens and/or epitopes (such as CMB305 and in our neoantigen collaboration); and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization (such as G100). 

Bank Name Immune Design Corp.
Stock Exchange NASDAQ
Symbol IMDZ
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
Chairman
CEO Dr. Carlos V. Paya
Employees 55
Website www.immunedesign.com
Registered Year 2008

UpdateContent
UpdateContent
UpdateContent